Atlas Trials

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Clinical trial NCT00386581 · COMPLETED

Trial details

NCT number
NCT00386581
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Attention Deficit Disorder With Hyperactivity
Start date
2004-07-01
Enrollment
105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.